| Document |
Document Title |
|
WO/2019/218864A1 |
Disclosed is a method of preparing an organic amine ester derivative drug of 2-(α-hydroxypentyl)benzoic acid and a use thereof. In particular, the present disclosure relates to a compound represented by formula I or a pharmaceutically a...
|
|
WO/2019/222105A1 |
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R20 –(Z)b–(Y)c–(R21)a–(X)d–R22–R23 wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted...
|
|
WO/2019/214084A1 |
Provided is a method for biocatalytic synthesis of Sitagliptin and intermediates thereof, in particular, provided are compounds of Formula (I) and Formula (II), or pharmaceutically acceptable salts thereof, a polypeptide capable of catal...
|
|
WO/2019/216355A1 |
The present invention relates to: a method for converting a hydroxyl group of an alcohol; and a catalyst which makes the method possible. A method for converting a hydroxyl group of an alcohol according to the present invention is charac...
|
|
WO/2019/216810A1 |
Compounds of the formulae wherein the bond α is a single bond, a trans double bond (E), or a triple bond; X and Y are -CH2- or on of X and Y is O and the other is CH2; R1 is phenyl unsubstituted or substituted with one, two, or three su...
|
|
WO/2019/217977A1 |
Disclosed herein are compounds represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g, inhib...
|
|
WO/2019/213160A1 |
This disclosure provides compounds with Bcl inhibitory activity. Acyl phosphonamidate compounds may include a P-phenyl phosphonamidate moiety which is N-acylated with an aroyl or heteroaroyl group. One of the heteroatoms attached to phos...
|
|
WO/2019/199864A1 |
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...
|
|
WO/2019/197366A1 |
The present document is directed to co-crystals of resveratrol and/or curcumin with piperazine and their use in medicine and/or as food and feed supplements.
|
|
WO/2019/193846A1 |
Provided is a novel production method for a compound. This production method for a compound (1) represented by the following general formula (1) (in the formula, R1 and R2 are independent of each other and are a fluorine atom or an organ...
|
|
WO/2019/192602A1 |
The present invention relates to an aromatic compound and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as shown in the following general formula (I), or a tautomer, an enantiomer, a diastereom...
|
|
WO/2019/190885A1 |
Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by...
|
|
WO/2019/188200A1 |
Provided is a production method for a lithium sulfamate. The production method for a lithium sulfamate is characterized by including a step (1) for reacting a compound (1) that is represented by general formula (1) (in which X is fluorin...
|
|
WO/2019/188717A1 |
The present invention addresses the problem of providing a compound which is capable of forming a radical polymerization initiator that exhibits excellent heat resistance and solubility. The present invention is a compound represented by...
|
|
WO/2019/175008A1 |
A process for removing methoxyethanol from a mixture comprising methoxyethanol and morpholine makes use of the selective absorption of methoxyethanol on a mixed oxide comprising a spinel phase. The mixed oxide contains 20% to 30% by weig...
|
|
WO/2019/177997A1 |
Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical com...
|
|
WO/2019/177142A1 |
The present invention provides: a prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation; a cell protection agent for transplantation; and a bio-preservation agent. A prophylactic or therapeut...
|
|
WO/2019/173507A1 |
The invention provides compounds of formula (I) or (II) and tautomers and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula (I) or (II) or a tautomer or salt ...
|
|
WO/2019/166623A1 |
The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyc...
|
|
WO/2019/168089A1 |
The purpose of the present invention is to provide: a novel compound which absorbs long-wavelength active energy rays and generates with high-efficiency radicals and strong bases, and which has excellent reaction efficiency in a base gen...
|
|
WO/2019/162121A1 |
The invention relates to a method for the continuous separation by distillation of mixtures containing morpholine (MO), monoaminodiglycol (ADG), ammonia, water and methoxyethanol (MOE), obtained by reacting diethylene glycol (DEG) with a...
|
|
WO/2019/162120A1 |
The invention relates to a method for depleting 2-methoxyethanol (MOE) from a mixture containing predominantly morpholine (MO) (crude morpholine), characterized in that crude morpholine is distilled in a distillation column in the presen...
|
|
WO/2019/159596A1 |
Provided is a method for preparing a coupled body represented by general formula (3), the coupled body being obtained by reacting a compound represented by general formula (1) and a compound represented by general formula (2) in the pres...
|
|
WO/2019/161308A1 |
The invention relates to the surprising discovery that TMZ and pharmaceutical salts thereof are an effective pharmacological agent in the treatment of certain decompensating patients with an underlying chronic liver condition. In particu...
|
|
WO/2019/155352A1 |
The present invention relates to a novel crystalline polymorphic form of 1-[2-(2,4-dimethyl- phenylsulfanyl)-phenyl]-piperazine hydrochloride; commonly known as vortioxetine hydrochloride (hereafter referred to as the compound (Ia) and p...
|
|
WO/2019/154284A1 |
The present invention relates to the pesticide field, and discloses a piperazinone derivative, a preparation method therefor, use thereof, an accelerator and a method for controlling root parasitic weeds. The piperazinone derivative has ...
|
|
WO/2019/154795A1 |
The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)eth
yl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxyt...
|
|
WO/2019/152536A1 |
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
|
|
WO/2019/150895A1 |
Provided is an electrolyte capable of improving the high-temperature storage characteristics and cycle characteristics of an electrochemical device. The electrolyte includes at least one type of compound indicated by general formula (1â€...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/144805A1 |
Provided are a substituted phenylethylamine compound as a μ opioid receptor agonist, a pharmaceutical composition comprising same, a preparation method therefor and the use of same for preventing and/or treating diseases associated with...
|
|
WO/2019/143782A1 |
A plasticized PVC composition free of phthalate is disclosed. The composition comprises a tertiary diamide plasticizer prepared from biorenewable feedstock such as fatty acid selected from tall oil fatty acids, tall oil fatty acid monome...
|
|
WO/2019/141740A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, X, Z, R2 and R3 are as described herein. The inventions further relates to compositions comprising said compounds, to meth...
|
|
WO/2019/142192A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...
|
|
WO/2019/139899A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/139902A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/139900A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/136112A1 |
The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmu...
|
|
WO/2019/125655A1 |
The disclosure is related to EMM-31 materials, processes, and uses of the same as reagents used in the preparation of the EMM-31 materials, process and intermediates for preparing these reagents.
|
|
WO/2019/115498A1 |
The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use ...
|
|
WO/2019/116260A1 |
A perfluorinated 1-alkoxypropene represented by general Formula (I), compositions that include such compounds, and methods and systems that include such compositions are provided, wherein Formula (I) is represented by: RfO-CF=CFCF3 where...
|
|
WO/2019/111225A1 |
Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein....
|
|
WO/2019/109934A1 |
The present invention provides a salt of a phenylpropionamide derivative and a preparation method therefor. The present invention specifically provides an acetate, hydrochloride, phosphate, citrate, benzoate, or fumarate of 4-amino-1-((2...
|
|
WO/2019/106490A1 |
The present invention is directed towards a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N- dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with trans-4- (2-(...
|
|
WO/2019/104030A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
|
|
WO/2019/103990A1 |
An electrically debondable adhesive composition is described. The adhesive is comprised of a basic ionic liquid and an optionally crosslinked polymer, wherein the basic ionic liquid is comprised of a cyclic amino-ammonium cation and a bi...
|
|
WO/2019/101142A1 |
The present invention provides a dibutylfluorene derivative, an application thereof as a photoinitiator, and a preparation method of the same. The present invention also provides a photocurable composition comprising the compound and a m...
|
|
WO/2019/099873A1 |
The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a signi...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/087626A1 |
Provided are: a compound which can be used suitably as a photodegradable base in a resist composition that has good sensitivity to an active energy, has excellent resolution in lithography and enables the reduction in line width roughnes...
|
